Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Midazolam

USE IF: Procedural sedation, status epilepticus, ICU sedation

AVOID IF: Severe respiratory depression without airway support

Midazolam

Benzodiazepine (short-acting GABA-A modulator)

SedationSeizuresICU sedationProcedural

Indication

Procedural sedation, status epilepticus, ICU sedation

At a glance

INDICATION -> Rapid-onset benzodiazepine for sedation, amnesia, and seizure control

ADULT DOSE -> Sedation 1 mg IV increments; seizure 0.1 mg/kg IV

MAX DOSE -> Procedural about 5 mg IV total (lower in elderly)

CONTRA -> Rapid IV bolus, opioid combination without monitoring, severe respiratory depression without support

ANTIDOTE -> Flumazenil

Quick facts

Onset

IV 1-3 min; IM 15-30 min

Duration

Peak 3-5 min; duration 30-60 min (single dose); half-life 1.5-3 h (prolonged in ICU).

Routes

IV, IM, PO, IN, buccal

Pregnancy

Avoid (neonatal depression risk)

Renal

Reduce dose

Hepatic

Reduce dose

Do not miss

Time to action: IV 1-3 min, IM 15-30 min

Respiratory risk

  • Respiratory depression risk is highest with opioids or rapid IV administration.

Critical risks

  • Rapid IV push can cause apnea/arrest.
  • Active metabolites accumulate -> prolonged sedation in renal failure and ICU infusions.
  • Active metabolite can prolong sedation.

Antidote

  • Flumazenil can precipitate seizures in dependent or mixed-overdose patients.

High-risk scenarios

  • Dose carefully in elderly; procedural total often <=5 mg IV.

Key interactions

  • CYP3A4 inhibitors.
  • CYP3A4 inducers.
  • Opioids.
  • Other sedatives/CNS depressants.

Indications

Primary

  • Procedural sedation
  • Status epilepticus
  • ICU sedation (intubated)

Secondary

  • Preoperative anxiolysis
  • Palliative sedation

Other

  • Acute agitation (adjunct)

Dosing

Standard: Sedation: 1 mg IV q2-3 min

Max daily dose

  • Procedural dosing is individualized; often around 5 mg IV total in adults (less in elderly).

Adult - IV

  • PO pre-procedure: 7.5-15 mg.
  • IV sedation: 1-2 mg titrated every 2-3 min.

Adult - IV

  • Seizure: 0.1 mg/kg IV.
  • Infusion: 0.02-0.1 mg/kg/hr (ICU).

Pediatric

  • IV: 0.05-0.1 mg/kg.
  • IN/buccal: 0.2 mg/kg for seizure rescue.

Renal adjustment

  • Reduce dose and avoid prolonged infusion when possible.

Hepatic adjustment

  • Reduce dose with slower titration.

Warnings

Clinical warnings

  • Respiratory depression/apnea risk.
  • Hypotension (especially IV dosing).
  • Causes hypotension via decreased systemic vascular resistance.
  • Delirium risk with ICU use.
  • Paradoxical agitation can occur.
  • Paradoxical agitation -> treat with flumazenil (if appropriate) or switch agent.
  • Short initial effect due to redistribution -> prolonged sedation with repeated dosing or infusion.
  • Prolonged sedation with infusion/organ dysfunction.
  • Opioids + benzodiazepines -> HIGH risk of respiratory depression and apnea.

Adverse effects

  • Common: drowsiness, amnesia, dizziness.
  • Serious: apnea, hypotension, prolonged coma-like sedation.

Contraindications / caution

Do not use

  • Acute narrow-angle glaucoma.
  • Severe respiratory depression without airway/ventilatory support.

Use caution / avoid high doses

  • Elderly.
  • Hepatic failure.
  • Renal failure.
  • Shock/hypotension.
  • Chronic benzodiazepine use.

Drug interactions

  • CYP3A4 inhibitors (azoles/macrolides) -> increased toxicity/sedation.
  • CYP3A4 inducers (e.g., rifampicin) -> reduced effect.
  • Opioids -> increased respiratory depression.
  • Other sedatives -> additive CNS depression.

Special populations

Pediatrics

Common for seizure rescue and procedural sedation with strict weight-based dosing.

Pregnancy

Avoid if possible due to neonatal depression risk.

Breastfeeding

Single dose likely low risk; repeated use requires caution.

Elderly

Start with about half-dose and titrate slowly.

Liver disease

Prolonged sedation risk; reduce dose.

Renal impairment

Active metabolite accumulation risk; reduce dose.

Administration

  • IV slow push over at least 2 minutes.
  • Titrate every 2-3 minutes to effect.
  • Continuous monitoring is required.
  • ICU infusions should use a pump.
  • IN/buccal route is important for seizures without IV access.

Monitoring

  • RR, SpO2, and BP.
  • Respiratory depression: CO2 retention occurs before SpO2 decline -> use capnography if available.
  • Sedation level (e.g., RASS).
  • Airway patency/ventilation.
  • Delirium monitoring in ICU use.
  • Renal and hepatic function with prolonged use.

Overdose / toxicity

Airway + ventilation -> monitor SpO2/CO2 -> flumazenil ONLY in selected low-risk patients -> supportive care.

Recognition

  • Toxic dose is variable and context-dependent.
  • CNS depression/coma with respiratory depression.

Immediate actions

  • Support airway and ventilation.
  • Hemodynamic support as needed.
  • Consider flumazenil only in selected low-risk scenarios.

Antidote

  • Flumazenil NOT routinely recommended -> risk of seizures in chronic benzodiazepine use or mixed overdose.

Decontamination

  • Not usually relevant in parenteral overdose.

Escalation

  • ICU if severe respiratory or hemodynamic compromise.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

Titration safety

  • Always titrate slowly; never push full dose rapidly.

Opioid pairing

  • Opioids + benzodiazepines -> HIGH risk of respiratory depression and apnea.

Flumazenil caution

  • Flumazenil is not routine and can precipitate seizures.

ICU practice

  • Daily sedation break can reduce accumulation and delirium risk.

Amnesia and profile

  • Causes anterograde amnesia - key for procedural sedation.
  • Midazolam = sedation + amnesia (NOT analgesia).
  • Provides sedation + amnesia but NO analgesia.
  • Slower onset than propofol -> safer but less predictable in bolus dosing.

Rescue route

  • IN/buccal route is key for seizure rescue when IV access is unavailable.

Pharmacokinetics

  • Rapid IV onset.
  • Hepatic metabolism via CYP3A4.
  • Active metabolite with renal clearance.
  • Accumulates in organ failure/prolonged infusion.

Mechanism of action

  • Positive allosteric modulation of GABA-A receptor.
  • Enhances inhibitory neurotransmission.

Common brand names

Saudi Arabia

Dormicum · Hikma Midazolam · Modzal

Global

Versed · Buccolam

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Widely used in GCC ER/ICU for sedation and seizure control.
  • Commonly stocked brands include Dormicum, Hikma Midazolam, and Modzal.
  • First-line benzodiazepine in many prehospital/EMS seizure protocols.
  • ICU sedation protocols emphasize dose reduction and daily sedation breaks.

Saudi Arabia — confirm with local formulary.